Fitoterapia, Journal Year: 2022, Volume and Issue: 162, P. 105278 - 105278
Published: Aug. 12, 2022
Language: Английский
Molecular Carcinogenesis, Journal Year: 2023, Volume and Issue: 63(1), P. 173 - 189
Published: Oct. 3, 2023
Abstract Lenvatinib is a clinically effective multikinase inhibitor approved for first‐line therapy of advanced hepatocellular carcinoma (HCC). Although resistance against lenvatinib often emerges and limits its antitumor activity, the underlying molecular mechanisms involved in endogenous acquired remain elusive. In this study, we identified focal adhesion kinase (FAK) as critical contributor to HCC. The elevated expression phosphorylation FAK were observed both lenvatinib‐resistant (LR) HCC cells. Furthermore, inhibition reversed vitro vivo. Mechanistically, promoted through regulating lysine‐deficient 1 (WNK1). Phosphorylation WNK1 was significantly increased LR‐HCC Further, WNK463 resensitized either established or cells treatment. addition, overexpression desensitized parental Conclusively, our results establish crucial role novel mechanism suggest that targeting FAK/WNK1 axis promising therapeutic strategy patients showing resistance.
Language: Английский
Citations
8
Nanomaterials, Journal Year: 2022, Volume and Issue: 12(12), P. 2048 - 2048
Published: June 15, 2022
The co-delivery of multiple drugs using nanocarriers has been recognized as a promising strategy for cancer treatment to enhance therapeutic efficacy. In this study, monodisperse mesoporous silica nanoparticle (mSiO2) is prepared and functionalized into high-efficiency loaded Lenvatinib Bufalin targeted delivery Cholangiocarcinoma (CCA). mSiO2 was synthesized on solid nanoparticles by oil-water interface method, highly with uniform morphology obtained. then sequentially modified polyethylene glycol (PEG) the targeting molecule folic acid (FA). mSiO2-FA designed system (Le) (Bu) increase drug availability target tumor cells. Compared unfunctionalized mSiO2, can more efficiently enter human CCA cell lines (9810 cells) intracellular delivery. Moreover, drug-loaded (Le/Bu@mSiO2-FA) significantly inhibited viability, migration invasion 9810 vivo, nanocomplex reduced load in tumor-bearing mouse models compared Le or Bu alone. current work provides useful multidrug-resistance reversal therapy CCA.
Language: Английский
Citations
11
Phytomedicine, Journal Year: 2024, Volume and Issue: 135, P. 156002 - 156002
Published: Sept. 1, 2024
Language: Английский
Citations
2
Journal of Inflammation Research, Journal Year: 2024, Volume and Issue: Volume 17, P. 10421 - 10440
Published: Dec. 1, 2024
Despite advancements in cancer treatment through surgery and drugs, hepatocellular carcinoma (HCC) remains a significant challenge, as reflected by its low survival rates. The mammalian target of rapamycin (mTOR) signaling pathway plays crucial role regulating the cell cycle, proliferation, apoptosis, metabolism. Notably, dysregulation leading to activation mTOR is common HCC, making it key focus for in-depth research current therapeutic strategies. This review focuses on downstream effectors HCC autophagy, metabolic reprogramming. Moreover, emphasizes potential natural products modulators pathway. When incorporated into combination therapies, these have been demonstrated augment efficacy surmount drug resistance. These pathways such pathways. Examples include 11-epi-sinulariolide acetate, matrine, asparagus polysaccharide. Their inhibitory effects processes suggest valuable directions development more effective Various ability inhibit suppress progression. phytochemicals, functioning inhibitors, hold great promise anti-HCC agents, especially context overcoming chemoresistance enhancing outcomes therapies.
Language: Английский
Citations
2
Fitoterapia, Journal Year: 2022, Volume and Issue: 162, P. 105278 - 105278
Published: Aug. 12, 2022
Language: Английский
Citations
8